{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:22Z","timestamp":1790286922161,"version":"4.1.0"},"reference-count":35,"publisher":"Informa UK Limited","issue":"17","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.2217\/fon-2022-1008","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T15:23:46Z","timestamp":1687879426000},"page":"1215-1227","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Rash with Different Types of BCR-ABL Inhibitors in Chronic Myelogenous Leukemia: A Systematic Review and Meta-Analysis"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-8618","authenticated-orcid":false,"given":"Su","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang,110042,Liaoning Province,PRChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-7661","authenticated-orcid":false,"given":"Tingwen","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Basic Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing,Jiangsu,211198,PRChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang,110042,Liaoning Province,PRChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang,110042,Liaoning Province,PRChina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0337"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2314-2"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25011"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01204-6"},{"key":"e_1_3_3_7_1","unstructured":"NCCN . NCCN clinical practice guidelines in oncology: chronic myeloid leukemia version 3.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"issue":"5","key":"e_1_3_3_9_1","first-page":"353","article-title":"The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)","volume":"41","author":"Chinese Society of Hematology, Chinese Medical Association","year":"2020","unstructured":"Chinese Society of Hematology, Chinese Medical Association . The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition). Chin. J. Hematol.41(5), 353\u2013364 (2020).","journal-title":"Chin. J. Hematol."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.032"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr"},{"issue":"3","key":"e_1_3_3_12_1","first-page":"e23288","article-title":"Bosutinib-induced Stevens\u2013Johnson syndrome and evidence of tolerance to a structurally dissimilar tyrosine kinase inhibitor","volume":"14","author":"Avila-Castano K","year":"2022","unstructured":"Avila-Castano K , Morgenstern-KaplanD, Carrillo-MartinI, Gonzalez-EstradaA. Bosutinib-induced Stevens\u2013Johnson syndrome and evidence of tolerance to a structurally dissimilar tyrosine kinase inhibitor. Cureus14(3), e23288 (2022).","journal-title":"Cureus"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12153"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00369.x"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03250.x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2008.00495.x"},{"issue":"10","key":"e_1_3_3_17_1","first-page":"1152","article-title":"[Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia]","volume":"46","author":"Shimizu K-I","year":"2005","unstructured":"Shimizu K-I , KurodaH, KidaMet al. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia]. Rinsho Ketsueki46(10), 1152\u20131155 (2005).","journal-title":"Rinsho Ketsueki"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194686"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12052"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410688"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544015"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12423"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-601674"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00080-2"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0957"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0805-1"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1600"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"issue":"24","key":"e_1_3_3_34_1","first-page":"7787","article-title":"Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence","volume":"25","author":"Ciftciler R","year":"2021","unstructured":"Ciftciler R , HaznedarogluIC. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur. Rev. Med. Pharmacol. Sci.25(24), 7787\u20137798 (2021).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2013.01.009"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.4274\/Tjh.2014.0021"},{"issue":"2","key":"e_1_3_3_37_1","first-page":"101","article-title":"Clinical characteristics, treatment pattern, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase by age","volume":"42","author":"Peng N","year":"2021","unstructured":"Peng N , DouXL, YuLet al. Clinical characteristics, treatment pattern, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase by age. Chin. J. Hematol.42(2), 101\u2013108 (2021).","journal-title":"Chin. J. Hematol."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-1008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:48Z","timestamp":1719125088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-1008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":35,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.2217\/fon-2022-1008"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-1008","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}